GlassScriptPhysician profile
Salman Zafar
NPI 1457319998
$13,829.98
in general payments reported to CMS, 2019-2025
44 companies · $672 in 2025
The $672 reported for 2025 was more than what 79% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,161 · 2020: $2,667 · 2021: $3,541 · 2022: $2,109 · 2023: $271 · 2024: $409 · 2025: $672.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,345 · Education: $6.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,345.47 |
| Education | $6.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,706.29 | 2019-2025 | Airsupra, Fasenra, Breztri |
| Novo Nordisk INC | $1,581.98 | 2019-2025 | Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,566.84 | 2019-2022 | |
| Amgen INC. | $1,288.89 | 2019-2022 | |
| Glaxosmithkline, LLC. | $801.70 | 2019-2022 | |
| Pfizer INC. | $649.13 | 2019-2022 | |
| Lilly USA, LLC | $515.02 | 2019-2023 | Jardiance |
| Janssen Pharmaceuticals, INC | $498.09 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $416.80 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $393.91 | 2019-2022 | |
| Eisai INC. | $364.70 | 2020-2022 | |
| Amarin Pharma, INC. | $330.44 | 2019-2022 | |
| Abbvie INC. | $266.04 | 2021-2022 | |
| Allergan, INC. | $260.83 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $245.47 | 2019-2024 | Xifaxan |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Salman Zafar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.